Evaluation Of Nuclear Matrix Protein 22 (NMP 22) As UrinarY Marker For Bladder Cancer

Abstract

In Egypt, tl1c urinary bladder malignancy represent a high incidence of

2o.30";;, of totaltnalignant tumors.

< \•stnscr>py i<; the mninstny of surveillance for bladder cancer, and frcq11cntlv is .sttppl cmentccl with 11rinc cytology.

/\lthn11gh cytology continttcs to he 8n ;JCcurate study for high grade bladder C<tncer. molecular 111mkers supposed to be more sensitive and more specific, have become av;Jil<thle t-ecently.

Food and Drug Administr;ttion (FDA) approval for monitoring of patients with hhddcr cancer has heen given to NMP22, FOP and BTA.

I he ;tim Pl. this work i.<; In c,•;tlttatc the clinical usefulness of urine cytology, Nttclc:tr M;ttrix Prntcin 22 (NMP..,7l nnd 1-'ihrin I Fibrinogen Degradation Products (FIW) in diagnosis ;mel follow 11p of hi adder cancer. This study included 60 patients and 20 healthy controls with matched age and sex. There vvere 30 patients with invasive bladder cancer (group I) , 20 patients (group If) under follow up cystoscopy after TURT [ among these : 7 J'nlicnts h:1d rcctwrcnt supcrfici;JI lt11nor (group !Ia) and 13 patients had free fin;tlh I() patients (group Ill) with other urologic

l'oticnts were sub.jected tn the . following:

I. Complete history taking.

11. Patients of group I & ll were subjected to PR examination and cystos('('I'Y• and the cystoscopic findings with confirmatory biopsies were cnns. iclcrcd the .Qold stnndard fnr di;JgJlPSi<;.